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CORRESPONDENCE
Letters to the Editor
Stress Cardiomyopathy
We were interested to see the report of Hurst et al. (1) describing
4 women with stress (tako-tsubo) cardiomyopathy and systolic
“midventricular ballooning.” As noted by the investigators, this left
ventricular (LV) contraction pattern differs from that of many
other patients with stress cardiomyopathy because the distal
portion of the chamber at the LV apex demonstrates a normal
contraction pattern (apical sparing). Indeed, in our initial report of
women with stress cardiomyopathy we also reported normal
contraction of the apical LV segment in 9 of 22 patients (41%)
based on cardiac magnetic resonance imaging (MRI) (2). In
addition, Abdulla et al. (3) also recently reported apical sparing in
14 of 35 patients (40%) with stress cardiomyopathy. Therefore,
this particular reversible pattern of abnormal LV contraction is
very common in stress cardiomyopathy, and it may well have been
an overestimation on the part of Hurst et al. (1) to regard this form
of the condition as a novel variant.
Conversely, such patients clearly represent a subset within this
disease spectrum, although of uncertain mechanism and clinical
significance at this time. This diversity of phenotypic expression
would, however, underscore the superiority of the term “stress
cardiomyopathy” to describe this diverse entity rather than the
ultimately confusing “midventricular ballooning” or “apical bal-
looning syndrome” (4–6). At this relatively early juncture in the
evolving description of stress cardiomyopathy, application of clear
and consistent nomenclature seems essential.
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Reply
We appreciate the interest of Dr. Sharkey and colleagues in our
report on transient midventricular ballooning of the left ventricle
(1). Even after careful review of the study by Sharkey et al. (2), we
are unable to find any evidence to substantiate their statement that
“we also reported normal contraction of the apical LV [left
ventricular] segment in 7 of 17 patients (41%) based on cardiac
MRI [magnetic resonance imaging].” To the contrary, in their
study the investigators state “All [our emphasis] exhibited a large
wall-motion abnormality that involved akinesia or hypokinesia of
the distal one-half to two-thirds of the LV chamber, which created
a distinctive ‘apical ballooning appearance’.” Accordingly, we are
unable to explain the discrepancy. The report by Abdulla et al. (3)
was published after our study was submitted, making it impossible
to have previously acknowledged.
Although the assertion that “this particular reversible pattern of
abnormal LV contraction is very common in stress cardiomyopa-
thy” may prove to be true, we did not comment on the prevalence
of transient midventricular ballooning in our study. In fact, it
would be anticipated that recognition of this midventricular variant
would increase through a heightened awareness of transient
ballooning syndrome, and this has proven correct as demonstrated
in the report by Abdulla et al. (3), the recent MRI image from
Steen et al. (4), and a case report by Shimizu et al. (5). We believe
the “novel” aspect of the cases was recognizing the implications in
determining the etiology underlying transient ballooning syn-
drome rather than the rarity of the occurrence.
The naming of this syndrome may be one of personal prefer-
ence; however, we would suggest that “transient ballooning syn-
drome” as a descriptive nomenclature seems most appropriate.
“Stress cardiomyopathy” implies a cause-and-effect relationship
that, at present, has not been fully elucidated. Stress is ubiquitous,
yet an associated transient cardiomyopathy is not!
*R. Todd Hurst, MD
Christina S. Reuss, MD
A. Jamil Tajik, MD
J. Wells Askew, MD
*Mayo Clinic Arizona
Cardiovascular Diseases
13400 East Shea Boulevard
Desk 3A
Scottsdale, Arizona 85260
E-mail: hurst.todd@mayo.edu
doi:10.1016/j.jacc.2006.12.003
Journal of the American College of Cardiology Vol. 49, No. 8, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc.
REFERENCES
1. Hurst RT, Askew JW, Reuss CS, et al. Transient midventricular
ballooning syndrome: a new variant. J Am Coll Cardiol 2006;48:
579 – 83.
2. Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible
cardiomyopathy provoked by stress in women from the United States.
Circulation 2005;111:472–9.
3. Abdulla I, Kay S, Mussap C, et al. Apical sparing in tako-tsubo
cardiomyopathy. Intern Med J 2006;36:414–8.
4. Steen H, Merten C, Katus H, Giannitsis E. A rare form of midven-
tricular tako-tsubo after emotional stress followed up with magnetic
resonance imaging. Circulation 2006;114:e248.
5. Shimizu M, Kato Y, Masai H, Shima T, Miwa Y. Recurrent episodes
of takotsubo-like transient left ventricular ballooning occurring in
different regions: a case report. J Cardiol 2006;48:101–7.
Contrast Nephropathy: Isosmolar
and Low-Osmolar Contrast Media
We read with interest the meta-analysis by McCullough et al. (1)
regarding the lower incidence of contrast-induced nephropathy
(CIN) in patients who received isosmolar contrast medium
(IOCM) iodixanol, as compared with those who received low-
osmolar contrast media (LOCM). Nevertheless, we believe the
study presents some important methodological limitations that
could reduce its value.
In the meta-analysis, the greater part of the patients (789 of
1,345) included in the group receiving LOCM were given an ionic
contrast medium (CM), and only 69 patients received iopamidol,
the contrast agent that, according to recent data, seems to be the
safest of the LOCM (2,3). Therefore, the results of the meta-
analysis could derive from the small number of patients receiving
iopamidol in the LOCM group, rather than to the renal safety of
isosmolar iodixanol. Moreover, apart from the small meta-analysis
by Clauss et al. (4) comparing the nephrotoxicity of the IOCM
iotrolan with different types of LOCM (iopamidol, iopromide, and
iohexol), the previous major comparative studies supporting the
possible safety of IOCM have been performed only between
iodixanol and the monomer iohexol (5–7), which is found to be
one of the CMs most responsible for CIN (2,3). Thus, at present,
we do not perceive any definitive evidence of the presumed
advantage derived from the use of IOCM in comparison with all
of the LOCM (8).
In addition, the investigators themselves note that only 18.3% of
patients included in the meta-analysis had their final creatinine
(Cr) values measured on day 3 or later (1), whereas CIN is defined
as an increase of serum Cr levels of 0.5 mg/dl (or 44 mol/l) or a
25% or greater relative increase from baseline 48 to 72 h after a
diagnostic or interventional procedure requiring CM administra-
tion (9). We would like to understand how the researchers
completed Table 4 in their study summarizing the incidence of
CIN occurring within 72 h if only 18.3% of patients have their Cr
values recorded on day 3.
Finally, as underscored by the investigators (1), another impor-
tant bias could be identified in the lack of data relative to the
amount or type of intravenous hydration prophylactic protocol
given before and after CM administration, which could influence
the outcomes of each trial (10).
We believe that prospective, double-blind, randomized, con-
trolled trials comparing iodixanol with all LOCM would be
necessary to confirm the results of this meta-analysis.
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Reply
Dr. Detrenis and colleagues point out that only 69 patients in the
low-osmolar contrast media (LOCM) group received iopamidol
and suggest it may be a special case among LOCM agents. As a
LOCM, iopamidol has an osmolality of 796 mOsm/kg H2O
(Isovue, Bracco Diagnostics, Princeton, New Jersey; 370 mg
iodine/ml, viscosity at 37°C, 9.4 Cp), which is very similar to
iohexol (844 mOsm/kg H2O, Omnipaque, Amersham Health,
Princeton, New Jersey; 350 mg iodine/ml, viscosity at 37°C, 10.4
Cp) (1,2). Both of these agents are nonionic monomers. By
contrast, iodixanol, an iso-osmolar contrast medium (IOCM), is a
nonionic dimer with an osmolality of 290 mOsm/kg H2O (Visi-
paque, Amersham Health, 320 mg iodine/ml, viscosity at 37°C,
11.6 Cp) and when compared to the nonionic LOCM monomers
in our study had a significantly lower rise in serum creatinine (Cr)
after contrast exposure (p  0.001) (3,4). Although iopamidol and
iohexol are nearly identical in their physiochemical properties as
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